Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.
PRADAXA is a direct thrombin inhibitor indicated:
Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process. Manufactured using the Wurster Coating Process, the layering of Dabired pellets, and the components of each layer, have been intricately designed and optimised applying QbD methodologies.
The Dabired Advantage
Dabired has successfully demonstrated in-vivo bio-equivalence which makes it possible to significantly accelerate your time to market.
Dabired pellets are ready to fill into capsules, and help reduce the steps to the complete formulation development
Dabired gives you a great reduction in cost including research , manpower along with freeing up manufacturing capacities.
Robust process design, packaging and analytical methods ensure well controlled impurity profile, including critical amide degradation impurities
Dabired comes to you in quantities that you need. It is available in stable packs, ranging from kilos to metric tonnes
The Complete Package
With Dabired, Dr. Reddy’s API business offers an integrated package of high-quality product, along with services that give you a distinct advantage.
Fully integrated expertise across API’s and formulation development, backed by bio-clinical and regulatory teams.
Capacities and supply chain plans are designed to meet global requirements for Dabired and the API.
Dabired brings global regulatory requirements, to enable your geographic expansion plans.
Our team of regulatory experts can support filing activities in countries of interest.
Knowledge transfer support, according to the customer requirements, to enable local manufacturing.
An experienced clinical pharmacokinetic team, available to extend their support.
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Dabired (Dabigatran Pellets) API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Dabired (Dabigatran Pellets) API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Please fill in the following form for API Requirement & we'll get back to you shortly
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. Please Contact Us for more information on availability and product suitability.
All product information, including that with regard to active pharmaceutical ingredients (API), the indication, and possible mechanism(s) of action, is based on publicly available product label.